However, this study still has some limitations: (1) There is no experimental verification of the impact of SLC35A3 methylation status on the phenotypes of CRC cells; (2) The effects of SLC35A3 on the malignant behavior of CRC cells were only explored in vitro experiments, and further evidence from in vivo experiments needs to be obtained in future studies; (3) The correlation between SLC35A3 expression and immune efficacy in CRC patients still needs to be further explored. The gene discussed is SLC35A3; the disease is colorectal carcinoma.